These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30026838)

  • 1. ELTD1 Function in Hepatocellular Carcinoma is Carcinoma-Associated Fibroblast-Dependent.
    Kan A; Le Y; Zhang YF; Duan FT; Zhong XP; Lu LH; Ling YH; Guo RP
    J Cancer; 2018; 9(14):2415-2427. PubMed ID: 30026838
    [No Abstract]   [Full Text] [Related]  

  • 2. Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1.
    Mao D; Wang H; Guo H; Che X; Chen M; Li X; Liu Y; Huo J; Chen Y
    Phytomedicine; 2024 Jan; 123():155191. PubMed ID: 38000104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of ELTD1, a pro-angiogenic adhesion GPCR.
    Favara DM; Banham AH; Harris AL
    Biochem Soc Trans; 2014 Dec; 42(6):1658-64. PubMed ID: 25399586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker.
    Serban F; Artene SA; Georgescu AM; Purcaru SO; Tache DE; Alexandru O; Dricu A
    Onco Targets Ther; 2015; 8():3767-74. PubMed ID: 26719704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK.
    Sun B; Zhong FJ
    Int J Gen Med; 2021; 14():4897-4911. PubMed ID: 34475781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression.
    Sheldon H; Bridges E; Silva I; Masiero M; Favara DM; Wang D; Leek R; Snell C; Roxanis I; Kreuzer M; Gileadi U; Buffa FM; Banham A; Harris AL
    Mol Cancer Res; 2021 Nov; 19(11):1957-1969. PubMed ID: 34348993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELTD1 Review: New Regulator of Angiogenesis in Glioma.
    Buzatu I; Tache DE; Manea Carneluti EV; Zlatian O
    Curr Health Sci J; 2023; 49(4):495-502. PubMed ID: 38559823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants.
    Favara DM; Banham AH; Harris AL
    BMC Evol Biol; 2019 Jul; 19(1):143. PubMed ID: 31299890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ELTD1-An Emerging Silent Actor in Cancer Drama Play.
    Sevastre AS; Buzatu IM; Baloi C; Oprita A; Dragoi A; Tataranu LG; Alexandru O; Tudorache S; Dricu A
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA AOC4P suppresses hepatocellular carcinoma metastasis by enhancing vimentin degradation and inhibiting epithelial-mesenchymal transition.
    Wang TH; Lin YS; Chen Y; Yeh CT; Huang YL; Hsieh TH; Shieh TM; Hsueh C; Chen TC
    Oncotarget; 2015 Sep; 6(27):23342-57. PubMed ID: 26160837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
    Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
    BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of the adhesion GPCR ADGRL4/ELTD1 promotes endothelial sprouting angiogenesis without activating canonical GPCR signalling.
    Favara DM; Liebscher I; Jazayeri A; Nambiar M; Sheldon H; Banham AH; Harris AL
    Sci Rep; 2021 Apr; 11(1):8870. PubMed ID: 33893326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
    Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
    Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts.
    Lin ZY; Chuang WL
    Kaohsiung J Med Sci; 2013 Jun; 29(6):312-8. PubMed ID: 23684136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of an ELTD1 knockout human embryonic stem cell line by the iCRISPR/Cas9 system.
    Luo Q; Wei C; Long Y; Zhang M; Shan W; Li H; Cai S; Xu Y; Qian P; Huang H
    Stem Cell Res; 2021 May; 53():102350. PubMed ID: 34087984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma.
    Chen CL; Wang Y; Pan QZ; Tang Y; Wang QJ; Pan K; Huang LX; He J; Zhao JJ; Jiang SS; Zhang XF; Zhang HX; Zhou ZQ; Weng de S; Xia JC
    Oncotarget; 2016 Mar; 7(13):16248-61. PubMed ID: 26919247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.